Dr. Maxime Cannesson, a pivotal figure in this movement and chair of the American Society of Anesthesiologists’ Center for Perioperative Medicine (CPMed), explains perioperative medicine as an organized, system-wide methodology that aligns surgeons, anesthesiologists, primary care specialists, nurses, and other healthcare professionals. This collaboration aims to optimize surgical care pathways and improve patient safety through meticulous risk stratification, procedural planning, and tailored interventions at every juncture of the surgical journey.

Fundamentally, perioperative medicine initiates with a detailed surgical risk assessment and a comprehensive evaluation of the patient’s physiological baseline. This preparatory phase involves correcting modifiable risk factors and optimizing medical conditions before surgery to elevate the patient’s baseline health status. During the operation itself, this approach ensures vigilant, evidence-based management by anesthesiologists and surgical teams to minimize physiological stress and potential complications. Postoperative care includes close monitoring, early mobilization, pain control, and interventions designed to facilitate swift recovery and reduce readmission rates.

Central to this model is a shift away from viewing surgical success solely through the lens of technical execution. Instead, perioperative medicine places equal importance on the patient’s quality of life, functional outcomes, and overall surgical experience. This patient-centric mindset emphasizes proactive communication, transparency, and early engagement of patients and families in surgical planning. According to Dr. Thomas R. Vetter, corresponding author of the journal article and an influential member of ASA’s Center for Perioperative Medicine, these initiatives translate to fewer surgery cancellations, more streamlined workflows, and a tangible reduction in perioperative complications—lead factors influencing both direct healthcare costs and long-term patient well-being.

The article distills insights from two recent perioperative medicine stakeholder summits held in 2024 and 2025, which assembled an array of global experts representing 14 distinguished professional societies. These gatherings highlighted how perioperative medicine is not only a clinical imperative but also a strategic response to overarching systemic challenges such as workforce shortages, staff burnout, and escalating accountability demands within value-based payment frameworks like the Centers for Medicare & Medicaid Services’ Transforming Episode Accountability Model (TEAM).

An integral aspect stressed in the article is the economic evaluation of perioperative interventions as healthcare systems transition towards episode-based reimbursements. Dr. Cannesson notes that perioperative medicine investments are justified by demonstrable improvements in care efficiency, patient-reported health metrics, and institutional workflows. This necessitates the establishment of robust governance structures, precise metrics, and financial alignment to sustain perioperative programs as essential institutional functions with measurable impact on both outcomes and costs.

Looking ahead, the CPAmed summits culminated in a visionary roadmap designed to anchor perioperative care improvements across four interconnected pillars: clinical practice, education, research, and leadership. The article underscores that advancements isolated to any single dimension will be insufficient. Rather, a harmonized approach integrating workforce training, standardized research methodologies for outcome assessment, and visionary leadership frameworks is critical to cultivating resilient multidisciplinary teams capable of meeting the complexities of modern surgical care.

The multi-stakeholder composition of the article’s authors reflects the broad consensus forming around perioperative medicine’s future. Contributions from entities such as the American College of Perioperative Medicine, Anesthesia Patient Safety Foundation, European Society of Anaesthesiology and Intensive Care, and the Veterans Health Administration illustrate the global nature of this clinical evolution. This consortium approach fosters a consistent, evidence-based foundation for practice guidelines that transcend geographic and institutional boundaries.

Technically, perioperative medicine leverages advancements in predictive analytics, enhanced recovery protocols, and patient engagement technologies. Real-time monitoring tools paired with machine learning algorithms enable dynamic risk profiling and personalized anesthetic management intraoperatively. Meanwhile, standardized enhanced recovery after surgery (ERAS) programs minimize surgical stress responses and support early functional recovery. These innovations align with perioperative medicine’s core philosophy of proactive, integrated care pathways that pre-empt complications and foster rapid return to baseline health.

Moreover, perioperative medicine addresses the psychological and social dimensions of surgical care by embedding communication strategies that emphasize clarity and empathy. Engaging patients early in shared decision-making contributes to reduced anxiety, better adherence to perioperative regimens, and more realistic expectations about recovery trajectories. This holistic approach reduces downstream resource utilization such as unplanned emergency visits or prolonged rehabilitation, thereby enhancing both patient satisfaction and system sustainability.

For healthcare administrators, perioperative medicine offers a strategic model for managing the growing complexities and costs associated with surgical volume expansion and aging populations. By instituting perioperative programs, institutions can reduce lengths of stay, minimize intensive care admissions, and improve throughput without compromising quality. Such system-level benefits are pivotal in today’s climate of constrained resources and evolving payment models emphasizing value and accountability.

The American Society of Anesthesiologists, since its founding in 1905, has actively championed anesthesiologists’ vital role in perioperative medicine, recognizing their expertise in managing the physiological intricacies of surgery and critical illness. ASA’s commitment to education, research, and advocacy positions it at the forefront of shaping perioperative medicine standards worldwide. This special article is both a testament to ongoing multidisciplinary collaboration and a clarion call for expanded research, innovation, and leadership to sustain momentum in this transformative field.

In conclusion, perioperative medicine epitomizes a new era in surgical care where integration, precision, and humanistic values converge to improve outcomes and patient experiences at every surgical juncture. It is a system-wide imperative that promises a safer, more efficient, and patient-centered future—anchored by robust evidence and unwavering multidisciplinary cooperation.

Subject of Research:
Article Title:
News Publication Date: 14-May-2026
Web References: https://pubs.asahq.org/anesthesiology, https://www.asahq.org/quality-and-practice-management/center-for-perioperative-medicine/summit, http://www.asahq.org/, https://www.asahq.org/madeforthismoment
References: American Society of Anesthesiologists, Center for Perioperative Medicine publications, CMS TEAM model documentation
Keywords: Perioperative Medicine, Surgical Care, Anesthesiology, Enhanced Recovery After Surgery, Multidisciplinary Collaboration, Patient Safety, Value-Based Healthcare, Risk Stratification, Predictive Analytics, Healthcare Innovation

Lung cancer remains a formidable adversary in oncology, with NSCLC accounting for the majority of cases. Despite advances in surgical techniques and perioperative management, postoperative recurrence continues to challenge long-term survival. Traditional staging and molecular markers, while informative, have shown limitations in predicting which patients may experience relapse. Addressing this critical gap, the research focused on the epigenetic landscape—a layer of regulation above the genome that influences gene expression without altering DNA sequences.

The team initiated their investigation by assembling a tissue DNA methylation cohort comprising 73 patients diagnosed with stage I to III NSCLC, all of whom had undergone surgical resection. This discovery set served as the foundation for developing a model centered on recurrence-free survival (RFS), a vital clinical endpoint representing the interval during which a patient remains free of cancer post-surgery. Employing advanced statistical and machine learning techniques, notably the least absolute shrinkage and selection operator (LASSO), they identified key differentially methylated regions (DMRs) indicative of recurrence risk.

The culmination of this approach was the establishment of the Early to Mid-term NSCLC Recurrence LASSO (EMRL) score, a composite biomarker signature encompassing five pivotal DMRs. This score was rigorously tested in an independent validation cohort of 30 patients within the same clinical stages, confirming its prognostic robustness. Crucially, the EMRL score demonstrated a statistically significant association with RFS, yielding compelling survival stratifications with a log-rank p-value of 0.00032, underscoring its predictive validity.

Beyond mere association, multivariate Cox regression analyses situated the EMRL score as an independent prognostic factor. With a hazard ratio (HR) of 0.35 and a narrow 95% confidence interval ranging from 0.20 to 0.61, the model confidently predicts a reduction in recurrence risk for patients characterized by specific methylation profiles. This independence from conventional clinical parameters, including tumor-node-metastasis (TNM) staging, elevates the EMRL score as a standout tool for individual risk assessment.

A particularly striking finding was the model’s capacity to discern high-risk individuals even within identical TNM stages—a traditionally coarse measure of disease extent. By revealing epigenetic heterogeneity overlooked by anatomical staging, the EMRL score refines prognostic precision and facilitates tailored postoperative surveillance strategies. This nuance could profoundly influence clinical decision-making, enabling more aggressive follow-up or adjuvant therapies for those flagged as high-risk.

Moreover, the study examined subpopulations harboring mutations known to influence treatment responsiveness, including the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)-sensitive mutations. The model retained its predictive power within these genetically defined groups, highlighting its adaptability and potential integration with existing molecular diagnostics. Similarly, patients exhibiting positive programmed death-ligand 1 (PD-L1) expression, a critical biomarker for immunotherapy candidacy, were also stratified effectively by the EMRL score, highlighting its broad applicability across diverse biological backgrounds.

Underpinning this research is an appreciation for DNA methylation’s role as a dynamic and reversible epigenetic mark that modulates gene expression in cancer. Unlike genetic mutations, methylation changes offer a more plastic and potentially therapeutically targetable mechanism shaping tumor behavior. By focusing on methylation “blocks” rather than isolated sites, the model captures broader epigenomic alterations that more accurately reflect tumor biology and progression tendencies.

The implications of these findings extend well beyond prognostication. The EMRL score opens avenues for early, personalized interventions in the perioperative window, a critical period where therapeutic decisions have lasting ramifications. Patients flagged as high-risk could benefit from intensified surveillance, adjunctive therapies, or enrollment in clinical trials testing novel agents aimed at epigenetic modulation or immune enhancement. Conversely, low-risk patients might avoid overtreatment and its associated morbidities, adhering to more conservative follow-up protocols.

From a technical perspective, the study’s methodology embodies the forefront of bioinformatics in clinical oncology. Utilizing high-throughput methylation profiling coupled with LASSO regression—a penalized model fostering sparse and interpretable predictors—the researchers navigated the complexity of epigenetic data to generate a clinically actionable score. This fusion of computational rigor with translational intent exemplifies modern precision medicine’s ethos.

The robustness of the EMRL score was further underscored through multivariate models controlling for age, gender, smoking status, tumor stage, and other relevant covariates. Its consistency across diverse patient subgroups attests to widespread utility, potentially enabling stratification across institutions with varying demographic and molecular landscapes. Such generalizability is paramount for broad clinical adoption.

Critically, the study argues for integrating epigenetic biomarkers alongside genomic and proteomic data to develop multidimensional predictive frameworks. Lung cancer’s heterogeneity demands multifaceted approaches, and DNA methylation represents a crucial, underexploited dimension. By demonstrating its prognostic relevance, this work paves the way for incorporating methylation signatures into routine diagnostic workflows.

Looking forward, prospective trials are essential to validate EMRL’s utility prospectively and to assess its impact on clinical outcomes under real-world conditions. Furthermore, exploring whether therapeutic modulation of identified DMRs could alter recurrence trajectories might unlock novel intervention strategies. The convergence of epigenetics and immuno-oncology, particularly given PD-L1 context, offers fertile ground for such innovation.

In summary, this pioneering study advances our understanding of NSCLC recurrence by harnessing epigenetic biomarkers to predict patient trajectories after surgical resection. The development and validation of the EMRL score not only enrich the prognostic toolkit but also exemplify the transformative potential of integrating molecular insights into clinical care. As personalized medicine continues to evolve, such models will be instrumental in delivering more nuanced, effective, and patient-centered treatment paradigms that ultimately improve survival and quality of life for lung cancer patients worldwide.

Subject of Research: Prognostic DNA methylation biomarkers predicting recurrence in non-small cell lung cancer patients following surgery

Article Title: Identification and validation of a DNA methylation-block prognostic model in non-small cell lung cancer patients

Article References:
Li, H., Lu, Y., Chen, H. et al. Identification and validation of a DNA methylation-block prognostic model in non-small cell lung cancer patients.
BMC Cancer 25, 999 (2025). https://doi.org/10.1186/s12885-025-14382-8

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14382-8